-
EP2825036
European procedure
Extract from the Register of European Patents
EP About this file: EP2825036
| EP2825036 - HISTIDINE ENGINEERED LIGHT CHAIN ANTIBODIES AND GENETICALLY MODIFIED RODENTS FOR GENERATING THE SAME [Right-click to bookmark this link] | |||
| Former [2015/04] | HISTIDINE ENGINEERED LIGHT CHAIN ANTIBODIES AND GENETICALLY MODIFIED NON-HUMAN ANIMALS FOR GENERATING THE SAME | ||
| [2017/37] | Status | No opposition filed within time limit Status updated on 08.03.2019 Database last updated on 09.04.2026 | |
| Former | The patent has been granted Status updated on 30.03.2018 | ||
| Former | Grant of patent is intended Status updated on 22.10.2017 | ||
| Former | Examination is in progress Status updated on 30.12.2016 | Most recent event Tooltip | 08.03.2019 | No opposition filed within time limit | published on 10.04.2019 [2019/15] | Applicant(s) | For all designated states Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591 / US | [2015/04] | Inventor(s) | 01 /
MCWHIRTER, John 2035 Crescent Drive Tarrytown, NY 10591 / US | 02 /
MACDONALD, Lynn 16 Gedney Way White Plains, NY 10605 / US | 03 /
MURPHY, Andrew, J. 10 Newton Court Croton-on-Hudson, NY 10520 / US | [2015/04] | Representative(s) | J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB | [N/P] |
| Former [2018/18] | J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB | ||
| Former [2015/04] | Bentham, Andrew J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB | Application number, filing date | 13713652.9 | 15.03.2013 | [2018/18] | WO2013US31823 | Priority number, date | US201261611950P | 16.03.2012 Original published format: US 201261611950 P | US201261736930P | 13.12.2012 Original published format: US 201261736930 P | [2015/04] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2013138680 | Date: | 19.09.2013 | Language: | EN | [2013/38] | Type: | A1 Application with search report | No.: | EP2825036 | Date: | 21.01.2015 | Language: | EN | The application published by WIPO in one of the EPO official languages on 19.09.2013 takes the place of the publication of the European patent application. | [2015/04] | Type: | B1 Patent specification | No.: | EP2825036 | Date: | 02.05.2018 | Language: | EN | [2018/18] | Search report(s) | International search report - published on: | EP | 19.09.2013 | Classification | IPC: | A01K67/027, C07K16/00, C12N15/85 | [2015/04] | CPC: |
A01K67/0278 (EP,CN,IL,US);
A01K67/0275 (CN,IL,RU,US);
C07K16/28 (IL,US);
C07K16/00 (EP,CN,IL,US);
C07K16/468 (CN,IL,US);
C12N15/8509 (EP,CN,IL,US);
A01K2207/15 (CN,IL,US);
A01K2217/072 (EP,CN,IL,US);
A01K2217/075 (EP,CN,IL,US);
A01K2217/15 (EP,CN,IL,US);
A01K2227/105 (EP,CN,IL,US);
A01K2267/01 (EP,CN,IL,US);
C07K2317/24 (CN,IL);
C07K2317/515 (EP,CN,IL,US);
C07K2317/56 (CN,IL,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2015/04] | Extension states | BA | Not yet paid | ME | Not yet paid | Title | German: | DURCH HISTIDIN MANIPULIERTE LEICHTKETTIGE ANTIKÖRPER UND GENETISCH MODIFIZIERTE NAGER ZUR ERZEUGUNG DAVON | [2017/37] | English: | HISTIDINE ENGINEERED LIGHT CHAIN ANTIBODIES AND GENETICALLY MODIFIED RODENTS FOR GENERATING THE SAME | [2017/37] | French: | ANTICORPS À CHAÎNES LÉGÈRES MODIFIÉS AVEC DE L'HISTIDINE ET RONGEURS GÉNÉTIQUEMENT MODIFIÉS POUR GÉNÉRER CES ANTICORPS | [2017/37] |
| Former [2015/04] | DURCH HISTIDIN MANIPULIERTE LEICHTKETTIGE ANTIKÖRPER UND GENETISCH MODIFIZIERTE, NICHTMENSCHLICHE TIERE ZUR ERZEUGUNG DAVON | ||
| Former [2015/04] | HISTIDINE ENGINEERED LIGHT CHAIN ANTIBODIES AND GENETICALLY MODIFIED NON-HUMAN ANIMALS FOR GENERATING THE SAME | ||
| Former [2015/04] | ANTICORPS À CHAÎNES LÉGÈRES MODIFIÉS AVEC DE L'HISTIDINE ET ANIMAUX NON HUMAINS GÉNÉTIQUEMENT MODIFIÉS POUR GÉNÉRER CES ANTICORPS | Entry into regional phase | 16.10.2014 | National basic fee paid | 16.10.2014 | Designation fee(s) paid | 16.10.2014 | Examination fee paid | Examination procedure | 16.10.2014 | Examination requested [2015/04] | 05.06.2015 | Amendment by applicant (claims and/or description) | 16.02.2016 | Despatch of a communication from the examining division (Time limit: M04) | 23.06.2016 | Reply to a communication from the examining division | 20.12.2016 | Despatch of a communication from the examining division (Time limit: M04) | 02.05.2017 | Reply to a communication from the examining division | 23.10.2017 | Communication of intention to grant the patent | 28.02.2018 | Fee for grant paid | 28.02.2018 | Fee for publishing/printing paid | 28.02.2018 | Receipt of the translation of the claim(s) | Divisional application(s) | EP15151655.6 / EP2883449 | EP18158960.7 / EP3348140 | EP20208322.6 / EP3808175 | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 16.02.2016 | Opposition(s) | 05.02.2019 | No opposition filed within time limit [2019/15] | Fees paid | Renewal fee | 24.03.2015 | Renewal fee patent year 03 | 23.03.2016 | Renewal fee patent year 04 | 23.03.2017 | Renewal fee patent year 05 | 23.03.2018 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X] WO2011097603 (REGENERON PHARMA et al.) | [XYI] EP2275443 (CHUGAI PHARMACEUTICAL CO LTD et al.) | [XYI] WO2011111007 (RINAT NEUROSCIENCE CORP et al.) | [Y] WO9203918 (GENPHARM INT et al.) | [Y] US5545806 (LONBERG NILS et al.) | [X] JAVIER CHAPARRO-RIGGERS ET AL: "Increasing Serum Half-life and Extending Cholesterol Lowering in Vivo by Engineering Antibody with pH-sensitive Binding to PCSK9", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 287, no. 14, 31 January 2012 (2012-01-31), pages 11090 - 11097, XP002684539, ISSN: 0021-9258, [retrieved on 20120131], DOI: 10.1074/JBC.M111.319764 DOI: http://dx.doi.org/10.1074/JBC.M111.319764 | [X] IGAWA T ET AL: "Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 28, no. 11, 1 November 2010 (2010-11-01), pages 1203 - 1207, XP009153598, ISSN: 1087-0156, DOI: 10.1038/NBT.1691 DOI: http://dx.doi.org/10.1038/nbt.1691 | [A] IGAWA TOMOYUKI ET AL: "Engineering the variable region of therapeutic IgG antibodies", MABS, LANDES BIOSCIENCE, US, vol. 3, no. 3, 1 May 2011 (2011-05-01), pages 243 - 252, XP009153597, ISSN: 1942-0870 | by applicant | US2011111406 | US2011195454 | US2012021409 | US2012192300 | US2013045492 | US2012192309 | US2007280945 | US2010331527 | US6586251 | US7294754 | US6596541 | US6774279 | LEFRANC ET AL., DEV. COMP. IMMUNOL., vol. 27, 2003, pages 55 - 77 | DEV. COMP. IMMUNOL., vol. 27, 2003, pages 55 - 77 | GONNET ET AL.: "Exhaustive Matching of the Entire Protein Sequence Database", SCIENCE, vol. 256, 1992, pages 1443 - 45, XP008148163, DOI: doi:10.1126/science.1604319 DOI: http://dx.doi.org/10.1126/science.1604319 | SIMISTER; MOSTOV: "An Fc receptor structurally related to MHC class I antigens", NATURE, vol. 337, 1989, pages 184 - 87, XP002616981, DOI: doi:10.1038/337184a0 DOI: http://dx.doi.org/10.1038/337184a0 | VALENZUELA: "High-throughput engineering of the mouse genome coupled with high-resolution expression analysis", NATURE BIOTECH., vol. 21, no. 6, 2003, pages 652 - 659 | KOHLER; MILSTEIN, NATURE, vol. 256, 1975, pages 495 - 497 | TUTT ET AL., J. IMMUNOL., vol. 147, 1991, pages 60 - 69 | KUFER ET AL., TRENDS BIOTECHNOL., vol. 22, 2004, pages 238 - 244 | VALENZUELA ET AL.: "High-throughput engineering of the mouse genome coupled with high-resolution expression analysis", NATURE BIOTECH., vol. 21, no. 6, 2003, pages 652 - 659 | POUEYMIROU ET AL.: "FO generation mice that are essentially fully derived from the donor gene-targeted ES cells allowing immediate phenotypic analyses", NATURE BIOTECH., vol. 25, no. 1, 2007, pages 91 - 99 |